Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05972733
Other study ID # NOR-215
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date August 2, 2023
Est. completion date November 10, 2023

Study information

Verified date January 2024
Source HilleVax
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to obtain serum for proficiency testing to confirm assay validity is maintained following the dosing of adults with a pediatric dose of HIL-214.


Description:

This single-arm trial serves to obtain serum for proficiency testing to confirm assay validity is maintained. Exploratory aspects of this trial include evaluating additional assays used for the assessment of immune responses to HIL-214 in peripheral-blood samples. Given the large volume of blood required, the pediatric dose will be tested in healthy adults. The main scientific rationale for the trial is to identify immune assays that can assess the generation of serum antibodies or cell-mediated immunity (CMI) specific to norovirus strains not represented in the HIL-214 vaccine (i.e. cross-reactivity).


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date November 10, 2023
Est. primary completion date August 14, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria: - Male or female subjects aged 18 to 49 years, inclusive. - Individuals who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator. - The individual signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to regulatory requirements. - Individuals willing and able to comply with trial procedures and are available for the duration of follow-up. Exclusion Criteria: - Females who are pregnant or breastfeeding. - Gastroenteritis within 14 days before planned dosing (can warrant delay of trial vaccine administration). - Known hypersensitivity or allergy to any of the HIL-214 components (including excipients). - Known or suspected impairment/alteration of immune function, including history of any autoimmune disease or neuro-inflammatory disease. - Any serious chronic or progressive disease (including hepatitis B or C). - Previous exposure to an experimental norovirus vaccine. - Subject or subject's first-degree relatives are involved in the trial conduct.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
HIL-214
HIL-214

Locations

Country Name City State
United States Pennisula Research Associates Rolling Hills Estates California
United States Clinical Research Atlanta Stockbridge Georgia

Sponsors (1)

Lead Sponsor Collaborator
HilleVax

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Immunogenicity for Panel Formation For the 80 subjects enrolled in the trial, the serum samples that will be collected will be used to produce a proficient assay panel based on immunogenicity results of the initial testing. This panel that is formed will be used for further analysis in other clinical trials. 6 months
See also
  Status Clinical Trial Phase
Completed NCT01168401 - Bivalent Norovirus Vaccine Study Phase 1
Completed NCT02541695 - Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli N/A
Completed NCT02473887 - Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting Phase 1
Completed NCT01911143 - A Retrospective, Blinded Validation of a Host-response Based Diagnostics N/A
Not yet recruiting NCT01671137 - Probiotic for the Prevention of Functional Disorders in Childhood N/A
Completed NCT01917461 - Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections N/A
Withdrawn NCT00691275 - Efficacy Study of IV Fluids Only vs Ondansetron to Treat Dehydration N/A
Recruiting NCT06025695 - Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks Phase 3
Completed NCT04463082 - Non-invasive Assessment of the Current State of Hydration in Children by Ultrasound N/A
Completed NCT02497417 - A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients N/A
Active, not recruiting NCT03000296 - Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease N/A
Completed NCT01236066 - Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia N/A
Completed NCT01225042 - The Effect of Probiotics on E. Coli Gastroenteritis N/A
Recruiting NCT00987519 - Viral Respiratory and Gastrointestinal Infections in Children Under 6 Years of Age N/A
Terminated NCT01357174 - ROTATEQâ„¢ Post-Marketing Surveillance in the Philippines N/A
Completed NCT01033799 - Effect of the Consumption of a Fermented Milk on Common Infections in Shift-workers N/A
Recruiting NCT01363726 - Surveillance of Rotavirus Gastroenteritis in Children <5 Years N/A
Completed NCT00130832 - Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED) Phase 3
Terminated NCT02568189 - Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration N/A
Terminated NCT02165813 - Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children Phase 2/Phase 3